Rescheduling Rumors and Organigram’s New Brand
Coming up at 11AM EST, on the latest episode of Trade To Black presented by Dutchie, hosts Shadd Dales and Anthony Varrell break down the latest rumors surrounding federal cannabis rescheduling—plus chatter that Canaccord Genuity could be relaunching coverage on several leading U.S. MSOs. We’ll also be joined by Organigram Global’s (NASDAQ: OGI) senior leadership to talk about the company’s new U.S. hemp-derived THC brand, Happly, which features targeted formulations for three key mood states: Socialize, Relax, and Sleep.
We welcome Organigram executives Megan McCrae and Borna Zlamalik to unveil their new edibles brand, Happly. The product targets a rising consumer segment interested in controlled, functional cannabis alternatives to alcohol. Available in most U.S. states via direct-to-consumer shipping, Happly features three mood-specific formulations—Socialize, Relax, and Sleep—each combining cannabinoids with functional ingredients like caffeine, L-theanine, and chamomile.
The products use Organigram’s proprietary FAST nanotechnology, developed through a 19-day clinical study, to deliver consistent onset (18–20 minutes) and enhanced bioavailability. McCrae explained the $90 million invested in R&D since the company’s inception enabled the team to build a consumer-driven, science-backed product that stands apart from typical THC edibles. Varrell and his own family tested the gummies, noting that even the low 2.5 mg THC doses hit harder thanks to the nanotech. A THCV-infused “Focus” gummy is currently in development.
As the market shifts away from alcohol, particularly among younger generations, Happly aims to fill the ritualistic and functional void with non-combustible, predictable cannabis options. McCrae noted that U.S. consumers are gravitating toward gummies and beverages, especially when available outside dispensaries. She confirmed discussions with national chains like Circle K and Walgreens to bring Happily further into the mainstream, alongside an upcoming beverage line. While Happly is launching DTC first, the brand plans to pilot retail placement later this year.
The brand is a product of Organigram’s innovation partnership with British American Tobacco, which began in 2021. BAT contributes scientific infrastructure while Organigram handles commercialization. With the U.S. market maturing rapidly, the team expects international expansion to follow in places like Australia and Germany as regulations evolve.
